Cell and gene therapy strategies to eradicate HIV reservoirs

Current Opinion in HIV and AIDS

Volumn 11, Issue 4, 2016, Pages 442-449

  Spragg, Chelsea ^a,b   De Silva Feelixge, Harshana ^a   Jerome, Keith R ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

CCR5; chimeric antigen receptor T cell; gene therapy; HIV cure; vector delivered antibody

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; ENVELOPE PROTEIN; NEUTRALIZING ANTIBODY;

CELL THERAPY; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; GENE DISRUPTION; GENE MUTATION; GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VIRUS GENOME; VIRUS REACTIVATION; VIRUS REPLICATION; BIOLOGICAL THERAPY; HIV INFECTIONS; MEDICAL RESEARCH; PROCEDURES; TRENDS; VIROLOGY; VIRUS LATENCY;

BIOMEDICAL RESEARCH; CELL- AND TISSUE-BASED THERAPY; GENETIC THERAPY; HIV INFECTIONS; HUMANS; VIRUS LATENCY;

EID: 84962120857     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000284     Document Type: Review

References (85)

1. Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15:893-900.
2. Soriano-Sarabia N, Archin NM, Bateson R, et al. Peripheral Vgamma9Vdelta2 T cells are a novel reservoir of latent HIV infection. PLoS Pathog 2015; 11:e1005201.
3. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5:512-517.
4. Siliciano JD, Kajdas J, Finzi D, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003; 9:727-728.
5. Hill AL, Rosenbloom DI, Fu F, et al. Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. Proc Natl Acad Sci U S A 2014; 111:13475-13480.
6. Hocqueloux L, Prazuck T, Avettand-Fenoel V, et al. Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS 2010; 24:1598-1601.
7. Saez-Cirion A, Bacchus C, Hocqueloux L, et al. Posttreatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013; 9:e1003211.
8. Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 2013; 369:1828-1835.
9. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5Delta32/ Delta32 stem-cell transplantation. N Engl J Med 2009; 360:692-698.
10. Allers K, Hutter G, Hofmann J, et al. Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood 2011; 117:2791-2799.
11. Mavigner M, Watkins B, Lawson B, et al. Persistence of virus reservoirs in ART-treated SHIV-infected rhesus macaques after autologous hematopoietic stem cell transplant. PLoS Pathog 2014; 10:e1004406.
12. Henrich TJ, Hanhauser E, Marty FM, et al. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med 2014; 161:319-327.
13. Duarte RF, Salgado M, Sanchez-Ortega I, et al. CCR5 Delta32 homozygous cord blood allogeneic transplantation in a patient with HIV: a case report. Lancet HIV 2015; 2:e236-e242.
14. Shimizu S, Yadav SS, An DS. Stable delivery of CCR5-directed shRNA into human primary peripheral blood mononuclear cells and hematopoietic stem/ progenitor cells via a lentiviral vector. Methods Mol Biol 2016; 1364:235-248.
15. Perez EE, Wang J, Miller JC, et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 2008; 26:808-816.
16. Holt N, Wang J, Kim K, et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 2010; 28:839-847.
17. Wang W, Ye C, Liu J, et al. CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection. PLoS One 2014; 9:e115987.
18. Li C, Guan X, Du T, et al. Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9. J Gen Virol 2015; 96:2381-2393.
19. Mock U, Machowicz R, Hauber I, et al. mRNA transfection of a novel TAL effector nuclease (TALEN) facilitates efficient knockout of HIV co-receptor CCR5. Nucleic Acids Res 2015; 43:5560-5571.
20. Tebas P, Stein D, Tang WW, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 2014; 370:901-910
21. Mandal PK, Ferreira LM, Collins R, et al. Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. Cell Stem Cell 2014; 15:643-652.
22. Wang J, DeClercq JJ, Hayward SB, et al. Highly efficient homology-driven genome editing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery. Nucleic Acids Res 2015; 18:e30.
23. Saydaminova K, Ye X, Wang H, et al. Efficient genome editing in hematopoietic stem cells with helper-dependent Ad5/35 vectors expressing sitespecific endonucleases under microRNA regulation. Mol Ther Methods Clin Dev 2015; 1:14057.
24. Sather BD, Romano Ibarra GS, Sommer K, et al. Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci Transl Med 2015; 7:307ra156.
25. Ye L, Wang J, Beyer AI, et al. Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Delta32 mutation confers resistance to HIV infection. Proc Natl Acad Sci U S A 2014; 111:9591-9596.
26. Kang H, Minder P, Park MA, et al. CCR5 disruption in induced pluripotent stem cells using CRISPR/Cas9 provides selective resistance of immune cells to CCR5-tropic HIV-1 virus. Mol Ther Nucleic Acids 2015; 4:e268.
27. Manotham K, Chattong S, Setpakdee A. Generation of CCR5-defective CD34 cells from ZFN-driven stop codon-integrated mesenchymal stem cell clones. J Biomed Sci 2015; 22:25.
28. Burke BP, Levin BR, Zhang J, et al. Engineering cellular resistance to HIV-1 infection in vivo using a dual therapeutic lentiviral vector. Mol Ther Nucleic Acids 2015; 4:e236.
29. Myburgh R, Ivic S, Pepper MS, et al. Lentivector knockdown of CCR5 in hematopoietic stem and progenitor cells confers functional and persistent HIV-1 resistance in humanized mice. J Virol 2015; 89:6761-6772.
30. Petit NY, Baillou C, Burlion A, et al. Gene transfer of two entry inhibitors protects CD4 T cell from HIV-1 infection in humanized mice. Gene Ther 2015; 23:144-150.
31. Jung U, Urak K, Veillette M, et al. Preclinical assessment of mutant human TRIM5alpha as an anti-HIV-1 transgene. Hum Gene Ther 2015; 26:664-679.
32. Scarborough RJ, Adams KL, Daher A, Gatignol A. Effective inhibition of HIV-1 production by short hairpin RNAs and small interfering RNAs targeting a highly conserved site in HIV-1 Gag RNA is optimized by evaluating alternative length formats. Antimicrob Agents Chemother 2015; 59:5297-5305.
33. Herrera-Carrillo E, Berkhout B. Gene therapy strategies to block HIV-1 replication by RNA interference. Adv Exp Med Biol 2015; 848:71-95.
34. Cheng Q, Dong L, Zhang F, et al. Short communication: efficiently inhibiting HIV-1 replication by a prototype foamy virus vector expressing novel H1 promoter-driven short hairpin RNAs. AIDS Res Hum Retroviruses 2015; 31:183-188.
35. Pandit A, de Boer RJ. HIV-1 CCR5 gene therapy will fail unless it is combined with a suicide gene. Sci Rep 2015; 5:18088.
36. Hou P, Chen S, Wang S, et al. Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection. Sci Rep 2015; 5:15577. This article demonstrates efficient disruption of the coreceptor CXCR4 using CRISPR/Cas9 and shows that division and propagation of primary CD4+ T cells is not affected.
37. Dar A, Kollet O, Lapidot T. Mutual, reciprocal SDF-1/CXCR4 interactions between hematopoietic and bone marrow stromal cells regulate human stem cell migration and development in NOD/SCID chimeric mice. Exp Hematol 2006; 34:967-975.
38. Nagasawa T, Nakajima T, Tachibana K, et al. Molecular cloning and characterization of a murine pre-B-cell growth-stimulating factor/stromal cellderived factor 1 receptor, a murine homolog of the human immunodeficiency virus 1 entry coreceptor fusin. Proc Natl Acad Sci U S A 1996; 93:14726-14729.
39. Le AQ, Taylor J, Dong W, et al. Differential evolution of a CXCR4-using HIV-1 strain in CCR5wt/wt and CCR532/32 hosts revealed by longitudinal deep sequencing and phylogenetic reconstruction. Sci Rep 2015; 5:17607.
40. Henrich TJ, Hanhauser E, Harrison LJ, et al. CCR5-delta32 heterozygosity, HIV-1 reservoir size, and lymphocyte activation in individuals receiving long-term suppressive antiretroviral therapy. J Infect Dis 2015; 213:766-770.
41. Symons J, Vandekerckhove L, Hutter G, et al. Dependence on the CCR5 coreceptor for viral replication explains the lack of rebound of CXCR4- predicted HIV variants in the Berlin patient. Clin Infect Dis 2014; 59:596-600.
42. Kordelas L, Verheyen J, Beelen DW, et al. Shift of HIV tropism in stem-cell transplantation with CCR5 delta32 mutation. N Engl J Med 2014; 371:880-882.
43. Barouch DH, Whitney JB, Moldt B, et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 2013; 503:224-228.
44. Shingai M, Nishimura Y, Klein F, et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 2013; 503:277-280.
45. Shingai M, Donau OK, Plishka RJ, et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J Exp Med 2014; 211:2061-2074.
46. Balazs AB, Chen J, Hong CM, et al. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 2012; 481:81-84.
47. Lewis AD, Chen R, Montefiori DC, et al. Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer. J Virol 2002; 76:8769-8775.
48. Johnson PR, Schnepp BC, Zhang J, et al. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 2009; 15:901-906.
49. Saunders KO, Wang L, Joyce MG, et al. Broadly neutralizing human immunodeficiency virus type 1 antibody gene transfer protects nonhuman primates from mucosal simian-human immunodeficiency virus infection. J Virol 2015; 89:8334-8345.
50. Martinez-Navio JM, Fuchs SP, Pedreno-Lopez S, et al. Host antiantibody responses following adeno-associated virus-mediated delivery of antibodies against HIV and SIV in rhesus monkeys. Mol Ther 2015; 24:76-86.
51. Fuchs SP, Martinez-Navio JM, Piatak M Jr, et al. AAV-delivered antibody mediates significant protective effects against SIVmac239 challenge in the absence of neutralizing activity. PLoS Pathog 2015; 11:e1005090.
52. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366:1275-1286.
53. Gardner MR, Kattenhorn LM, Kondur HR, et al. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature 2015; 519:87-91.
54. Nault JC, Datta S, Imbeaud S, et al. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet 2015; 47:1187-1193.
55. Berns KI, Byrne BJ, Flotte TR, et al. Adeno-associated virus type 2 and hepatocellular carcinoma? Hum Gene Ther 2015; 26:779-781.
56. Buning H, Schmidt M. Adeno-associated vector toxicity: to be or not to be. Mol Ther 2015; 23:1673-1674.
57. Asokan A, Schaffer DV, Samulski RJ. The AAV vector toolkit: poised at the clinical crossroads. Mol Ther 2012; 20:699-708.
58. Leibman RS, Riley JL. Engineering T cells to functionally cure HIV-1 infection. Mol Ther 2015; 23:1149-1159.
59. Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 2011; 121:1822-1826.
60. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365:725-733.
61. Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells:CARs take the front seat for hematologic malignancies. Blood 2014; 123:2625-2635.
62. Kochenderfer JN, Yu Z, Frasheri D, et al. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 2010; 116:3875-3886.
63. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012; 119:2709-2720.
64. Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013; 5:177ra138.
65. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368:1509-1518.
66. Scholler J, Brady TL, Binder-Scholl G, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 2012; 4:132ra153.
67. Kamata M, Kim PY, Ng HL, et al. Ectopic expression of anti-HIV-1 shRNAs protects CD8(+) T cells modified with CD4zeta CAR from HIV-1 infection and alleviates impairment of cell proliferation. Biochem Biophys Res Commun 2015; 463:216-221.
68. Zhen A, Kamata M, Rezek V, et al. HIV-specific immunity derived from chimeric antigen receptor-engineered stem cells. Mol Ther 2015; 23:1358-1367.
69. De Silva Feelixge HS, Stone D, Pietz HL, et al. Detection of treatment-resistant infectious HIV after genome-directed antiviral endonuclease therapy. Antiviral Res 2015.
70. Wang G, Zhao N, Berkhout B, Das AT. CRISPR-Cas9 can inhibit HIV-1 replication but NHEJ repair facilitates virus escape. Mol Ther 2016; 24:522-526.
71. Qu X, Wang P, Ding D, et al. Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells. Nucleic Acids Res 2013; 41:7771-7782.
72. Ebina H, Misawa N, Kanemura Y, Koyanagi Y. Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep 2013; 3:2510.
73. Hu W, Kaminski R, Yang F, et al. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc Natl Acad Sci U S A 2014; 111:11461-11466.
74. Zhu W, Lei R, Le Duff Y, et al. The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA. Retrovirology 2015; 12:22.
75. Ebina H, Kanemura Y, Misawa N, et al. A high excision potential of TALENs for integrated DNA of HIV-based lentiviral vector. PLoS One 2015; 10:e0120047.
76. Liao HK, Gu Y, Diaz A, et al. Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells. Nat Commun 2015; 6:6413.
77. Hall Sedlak R, Niyonzima N, Harshana D, et al. Digital detection of endonuclease mediated gene disruption in the HIV provirus. Sci Rep 2016; 6:20064.
78. Schumann K, Lin S, Boyer E, et al. Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proc Natl Acad Sci U S A 2015; 112:10437-10442.
79. Dampier W, Nonnemacher MR, Sullivan NT, et al. HIV excision utilizing CRISPR/Cas9 technology: attacking the proviral quasispecies in reservoirs to achieve a cure. MOJ Immunol 2014; 1:00022.
80. Zhou Q, Uhlig KM, Muth A, et al. Exclusive transduction of human CD4+ T cells upon systemic delivery of CD4-targeted lentiviral vectors. J Immunol 2015; 195:2493-2501.
81. Archin NM, Liberty AL, Kashuba AD, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012; 487:482-485.
82. Gane EJ, Lim YS, Gordon SC, et al. The oral toll-like receptor-7 agonist GS- 9620 in patients with chronic hepatitis B virus infection. J Hepatol 2015; 63:320-328.
83. Khaitan A, Unutmaz D. Revisiting immune exhaustion during HIV infection. Curr HIV/AIDS Rep 2011; 8:4-11.
84. Peligero C, Argilaguet J, Guerri-Fernandez R, et al. PD-L1 blockade differentially impacts regulatory T cells from HIV-infected individuals depending on plasma viremia. PLoS Pathog 2015; 11:e1005270.
85. Akhmetzyanova I, Drabczyk M, Neff CP, et al. PD-L1 expression on retrovirusinfected cells mediates immune escape from CD8+ T cell killing. PLoS Pathog 2015; 11:e1005224.